The Chemours Company Earnings Call Transcripts
Fiscal Year 2025
-
Strong Q4 cash flow and record TSS Opteon sales drove results, with 2026 guidance targeting 3%-5% sales growth and $800M-$900M Adjusted EBITDA. Strategic asset sales and cost initiatives support deleveraging and improved free cash flow conversion.
-
Q3 2025 results exceeded expectations, led by strong Opteon sales and cost controls, while TiO₂ demand remained weak. Guidance anticipates sequential sales and EBITDA declines in Q4, but 2026 is expected to bring growth and improved cash flow.
-
Q2 2025 results exceeded expectations with strong growth in TSS and progress on environmental settlements. Operational disruptions in TT and APM impacted results but are being addressed. Full-year guidance remains robust, with >5% sales growth expected in 2026, led by TSS.
-
Q1 saw strong Opteon demand and cost discipline, but lower pricing and restructuring led to a net loss. Guidance for 2025 was refined, with improved outlooks for TSS and TT, a dividend cut to boost flexibility, and a focus on operational excellence and growth initiatives.
-
Chemours outlined its growth strategy, emphasizing cost reductions, portfolio optimization, and innovation in refrigerants and data center cooling. The company is managing PFAS liabilities, expects double-digit TSS growth in 2025, and remains focused on operational excellence and market recovery.
Fiscal Year 2024
-
Q4 and full-year 2024 results exceeded Adjusted EBITDA expectations, driven by cost savings and strong Opteon™ refrigerant growth, despite macro headwinds. 2025 guidance anticipates improved earnings, continued cost reductions, and disciplined capital allocation.
-
Third-quarter results showed strong operational execution, record Opteon sales, and robust cost savings, though pricing pressures and a non-cash impairment led to a net loss. The refreshed strategy targets $250M+ in cost savings and growth in high-value markets, with continued focus on litigation resolution and disciplined capital allocation.
-
Q2 2024 saw lower sales and earnings due to pricing pressure, regulatory impacts, and a major production disruption, but strong Opteon growth and cost savings offset some headwinds. The outlook anticipates continued challenges in Q3, with recovery expected as regulatory and market dynamics improve.